Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a causative pathogen of Coronavirus Disease 2019 (COVID-19), rapidly grew into a global pandemic in 2019/2020. It is no secret that COVID-19 has caught the world population by surprise and will definitely challenge not only the healthcare system, but also the global economy for the future.

Regarding the fact that no effective and safe vaccine against given highly virulent virus has been approved yet, current research provided insight into diverse pharmacological strategies how to combat the pandemic threat. Moreover, taxomomy and structure of SARS-CoV-2, brief description of its life (replication) cycle in host cells, proposed mechanisms of action of selected promising anti-SARS-CoV-2 agents and their chemical structure were introduced as well. Some compounds which can be found in a group of marketed and experimental direct-acting antivirals, e.g., favipiravir, remdesivir or galidesivir, have shown ability to inhibit not only RNA-dependent RNA polymerase of SARS-CoV-2 but also the polymerases of different RNA viruses. In addition, umifenovir (arbidol) might be consider an effective anti-SARS-CoV-2 mo­lecule, which fight the pathogen by multiple mechanisms.
Key words: SARS-CoV-2, favipiravir, remdesivir, umifenovir, RNA-dependent RNA polymerase.
Lek Obz, 2020, 69 (9): 307-313


1Institute of Chemistry, Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Slovak Medical University in Bratislava, Head of Institute Prof. MUDr. RNDr. G. Kováč, CSc., MBA
2Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University in Bratislava, Head of DepartmentAssoc. Prof. Mgr. F. Andriamainty, PhD.


Ivan MALÍK, Gustáv KOVÁČ, Lucia HUDECOVÁ: Recent therapeutic options for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lek Obz, 2020, 69 (9): 307-313

Login Form